focus -WSS

focus

author：leisure time 2025-09-06 05:26:40 - browse：5

Why are rich biotechs cutting costs? Has JPM Week already worn off? And what’s going to move markets in 2024?

We cover all that and more this week on “The Readout LOUD,” STAT’s biotech podcast. Our colleague Jason Mast joins us to discuss an emerging trend in biotech: Cash-rich startups are laying off employees and tweaking their strategies amid a tough market for venture capital. We also look ahead to the biggest biotech stories coming in 2024, including some major data readouts and a few pivotal FDA decisions.

For more on what we cover, here’s the news on Dewpoint Therapeutics; here’s more on biotech in 2024; here’s where you can find episodes of Color Code; here’s where you can subscribe to the First Opinion Podcast; and here’s where you can subscribe to our biotech newsletter, The Readout.

Be sure to sign up on Apple Podcasts, Spotify, Stitcher, TuneIn, or wherever you get your podcasts.

And if you have any feedback for us — topics to cover, guests to invite, vocal tics to cease — you can email [email protected].

Previous article： Continuity nursing helped my family in our darkest PICU moments
Next article： Teladoc has a new CEO, but challenges remain the same

hotspot

WSS

Statins may not be needed by millions of people, study suggests

What is STAT's opinion section for?

Readout LOUD Podcast: Lilly's obesity drug, the power of radiation

Coercive sterilizations revealed by STAT prompt outrage

Readout LOUD Podcast: Lilly's obesity drug, the power of radiation

Lilly's Alzheimer's drug donanemab backed by FDA advisers

Wikipedia

focus

hotspot

Medicare proposal to cover medical devices draws a mixed reaction

NIH tests clinical research in primary care with $30 million program

Alkermes shareholders re

What health policies could hitch a ride on a spending bill?

Trump demands the U.S. pay no more for drugs than other countries … again

FDA reorg will put new emphasis on investigations, sources say

Virginia high school admissions case could be legal follow

How state and local governments are sidelining science

Medical leaders decry Supreme Court decision on affirmative action

Ohio still needs to do more to protect the right to abortion

entertainment

Cheap, fast test for Zika and dengue could cost just $1

Stephen Quake on the Chan Zuckerberg quest to conquer disease

'Essentially witchcraft:' A former naturopath takes on the field

Study suggests Covid rebound is far more common with Paxlovid than without

CVS, Rite Aid closures threaten to worsen pharmacy deserts

Curing rare childhood diseases will falter unless Congress steps up

hotspot

hotspot

focus

knowledge